Vivek Ramaswamy’s brother, Shankar, spins out on his own, launching audacious gene therapy play
In 2018, when Vivek Ramaswamy’s Axovant failed multiple trials on its lead dementia drug and pivoted the entire company toward gene therapy, one …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
